Technology | 2009.12.18
PolyMedix Successfully Completes Main Portions of Phase 1B Clinical Study with PMX-30063 Novel Antibiotic Drug Candidate
RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has successfully completed the first two segments of a Phase 1B clinical safety study with its novel antibiotic drug candidate PMX-30063. We believe PMX-30063 is the first and only small-molecule mimetic of host defense proteins in clinical development intended for systemic administration, wit
For more information, please visit
http://www.businesswire.com/news/home/20091218005098/en
